Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2004-07-21
2009-10-27
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S085200, C530S351000, C435S069700, C536S023400
Reexamination Certificate
active
07608267
ABSTRACT:
The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X; it also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule; it also relates to infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles; is also relates to a method for recombinantly producing such a fusion protein; and, lastly, it also relates to a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
REFERENCES:
patent: 198 23 351 (1998-12-01), None
patent: 0 158 198 (1985-10-01), None
patent: 0 225 579 (1987-06-01), None
patent: 0 288 809 (1988-11-01), None
patent: 0 816 510 (1998-01-01), None
patent: 0 816 510 (1998-01-01), None
patent: WO 93/20849 (1993-10-01), None
patent: WO 94/21792 (1994-09-01), None
patent: WO 98/08947 (1998-03-01), None
patent: WO 98/40498 (1998-09-01), None
patent: WO 99/36440 (1999-07-01), None
patent: WO 99/60128 (1999-11-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 01/10912 (2001-02-01), None
patent: WO 01/10912 (2001-02-01), None
patent: WO 01/68896 (2001-09-01), None
patent: WO 01/93898 (2001-12-01), None
patent: WO 02/22805 (2002-03-01), None
patent: WO 02/101049 (2002-12-01), None
patent: WO 02/102404 (2002-12-01), None
patent: WO 03/035105 (2003-05-01), None
patent: WO 03/035105 (2003-05-01), None
patent: WO 03/048334 (2003-06-01), None
Kim, S-H. H., et al. Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. 2000. Proc. Natl. Acad. Sci, USA. vol. 98(6), p. 3304-3309.
Danthinne X. et al. Production of first generation adenovirus vectors: a review. 2000. Gene Therapy. vol. 7, p. 1707-1714.
He Z. et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. 2000. Virology. vol. 270, p. 146-161.
Koyama, F. et al. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer ofEscherichia colicytosine deaminase gene andEscherichia coli coliuracil phosphoribosyltranferase gene with 5-fluorocytosine. 2000. Cancer Gene Therapy. vol. 7, p. 1015-1022.
Mickle JE et al. Genotype-phenotype relationships in cystic fibrosis. 2000. Med. Clin. North Am. vol. 84, No. 3, p. 597-607.
Okamoto M, et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. 2002. Blood. vol. 99, No. 4, p. 1289-1298.
Shan D. et al. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J. Immunol. 1999. vol. 162, p. 6589-6595.
Wigginton et al., “Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and Fas-Ligand-Dependent Tumor Education by Combined Administration of IL-18 and IL-2”, The Journal of Immunology, Oct. 2002, pp. 4467-4474, vol. 169, No. 8, The American Association of Immunologist, Inc.
Son et al., “Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-γ Production, and Expansion of Natural Killer Cells”, Cancer Research, Feb. 2001, pp. 884-888, vol. 61, No. 3.
Wang et al., “Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma”, Gene Therapy, Apr. 2001, pp. 542-550, vol. 8, No. 7, Nature Publishing Group.
Rock et al., “Overexpression and structure-function analysis of a bioengineered IL-2/IL-6 chimeric lymphokine”, Protein Engineering, Sep. 1992, pp. 583-591, vol. 5, No. 6, Oxford University Press, Surrey, GB.
Kaufmann et al., “Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells”, Immunobiology, Oct. 2000, pp. 339-352, vol. 202, No. 4, Urban & Fischer Verlag, Germany.
Kondo et al., “Enhancement of Interleukin-2-Induced Lymphokine-Activated Killer Activity by Interleukin 7 against Autologous Human Renal Cell Carcinoma”, Oncology, Nov. 1998, pp. 588-593, vol. 55, No. 6, Switzerland.
Ju et al., “Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity”, J. Cancer Res. Clin. Oncol., 1998, pp. 683-689, vol. 124, No. 12, Springer-Verlag.
Shanafelt et al., “A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo”, Nature Biotechnology, Nov. 2000, pp. 1197-1202, vol. 18, No. 11, Nature America, Inc.
International Search Report corresponding to PCT/EP 2004/008114, issued Mar. 31, 2005, 15 pages.
Ozdemir Oner et al., “Interleukin-2 and Interleukin-15 Combination Induces Lymphokine Activated Killers Cells with Higher Perforin and Granzyme B Expression Patterns and Superior Cytotoxic Response Against Human Leukemia Cells” 2002, vol. 100, No. 11, pp. Abstract No. 1827, XP-008082545.
Bagriacik E Umit et al., “CD43 Potentiates CD3-Induced Proliferation of Murine Intestinal Intraepithelial Lymphocytes” Immunology and Cell biology, 2001, vol. 79, No. 3, pp. 303-307, XP-002447489.
Vazquez Nancy et al., “Interleukin-15 Augments Superoxide Production and Microbicidal Activity of Human Monocytes AgainstCandida albicans” Infection and Immunity, 1998, vol. 66, No. 1, pp. 145-150, XP-002447490.
Dobmeyer T S et al., “Mechanism of gamma sigma T-Cell-Mediated Inhibition of Stem Cell Differentiation in Vitro: Possible Relevance for Myelosuppression in HIV-Infected Individuals” Cellular Immunology , 1998, vol. 184, No. 1, pp. 26-36, XP-002447491.
Ma Averil e al., “The Pleiotropic Functions of Interleukin 15: Not so Interleukin 2-like After All” Journal of Experimental Medicine, 2000, vol. 191, No. 5, pp. 753-755, XP-002169910.
Bulfone-Paus S et al., “Differential Regulation of Human T Lymphoblast Functions by IL-2 and IL-15” Cytokine, 1997, vol. 9, No. 7, pp. 507-513, XP-002230804.
Buchanan Ingersoll & Rooney P.C.
Hissong Bruce D
Landsman Robert
Transgene S.A.
LandOfFree
Multifunctional cytokines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multifunctional cytokines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multifunctional cytokines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4067610